CLASS ACTION UPDATE for DNKEY, YRCW, ATVI and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders


NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Danske Bank A/S (OTCMKTS: DNKEY)
Class Period:
Purchasers of American Depositary Receipts between January 9, 2014 and October 23, 2018
Lead Plaintiff Deadline: March 11, 2019
Join the action: https://www.zlk.com/pslra-1/danske-bank-a-s-loss-form?wire=3

The lawsuit alleges: Danske Bank A/S made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) Danske Bank’s Estonian branch was facilitating money laundering through at least March 2016; (ii) a whistleblower had reported the Estonian money laundering to the Company in 2013; (iii) Denmark’s Financial Supervisory Authority (the “DFSA”) had been investigating the Estonian money laundering since 2014; (iv) Danske Bank had concealed the results of its own internal investigation from the DFSA, further exposing it to regulatory action and fines; (v) Danske Bank had been overstating its historical profits by including the profits derived from its illicit Estonian operations; and (vi) Danske Bank lacked effective internal and reporting controls.

To learn more about the Danske Bank A/S class action contact jlevi@levikorsinsky.com.

YRC Worldwide Inc. (NASDAQGS: YRCW)
Class Period:
March 10, 2014 - December 14, 2018
Lead Plaintiff Deadline: March 4, 2019
Join the action: https://www.zlk.com/pslra-1/yrc-worldwide-inc-loss-form?wire=3

The lawsuit alleges: YRC Worldwide Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) from 2005 to at least 2013, YRC's units systematically overcharged the federal government for freight carrier services; (2) this alleged misconduct caused the Department of Defense to overpay by millions of dollars for shipments that were lighter, and thus cheaper, than the weights for which the government was charged; (3) consequently, this alleged misconduct would subject YRC to enhanced government scrutiny and liabilities, including potentially owing treble damages under the False Claims Act; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

To learn more about the YRC Worldwide Inc. class action contact jlevi@levikorsinsky.com.

Activision Blizzard, Inc. (NASDAQ: ATVI)
Class Period:
August 2, 2018 - January 10, 2019
Lead Plaintiff Deadline: March 19, 2019
Join the action: https://www.zlk.com/pslra-1/activision-blizzard-inc-loss-form?wire=3

The lawsuit alleges: Activision Blizzard, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) the termination of Activision Blizzard and Bungie's partnership, giving Bungie full publishing rights and responsibilities for the Destiny franchise, was imminent; (ii) the termination of the two companies' relationship would foreseeably have a significant negative impact on Activision Blizzard's revenues; and (iii) as a result, Activision Blizzard's public statements were materially false and misleading at all relevant times.

To learn more about the Activision Blizzard, Inc. class action contact jlevi@levikorsinsky.com.

Tyme Technologies, Inc. (NASDAQCM: TYME)
Class Period:
March 14, 2018 - January 18, 2019
Lead Plaintiff Deadline: March 29, 2019
Join the action: https://www.zlk.com/pslra-1/tyme-technologies-inc-loss-form?wire=3

The lawsuit alleges: Tyme Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (ii) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (iii) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (iv) as a result, Tyme’s public statements were materially false and misleading at all relevant times.

To learn more about the Tyme Technologies, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com